Grant Skrepnek to Drug Costs
This is a "connection" page, showing publications Grant Skrepnek has written about Drug Costs.
Connection Strength
0.763
-
Assessment of the effect of an enhanced prior authorization and management program in a United States Medicaid program on chronic hepatitis C treatment adherence and cost. J Am Pharm Assoc (2003). 2018 Sep - Oct; 58(5):485-491.
Score: 0.598
-
Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid. J Manag Care Spec Pharm. 2018 Jul; 24(7):664-676.
Score: 0.149
-
Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Curr Med Res Opin. 2007 Feb; 23(2):251-8.
Score: 0.017